Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOTUM | Q6P988 | 1/20 | 0.40 |
| ▸ | GPR183 | P32249 | 5/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | PROKR1 | Q8TCW9 | 1/20 | 0.34 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.34 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.34 |
| ▸ | EBP | Q15125 | 1/20 | 0.33 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.33 |
| ▸ | DHCR7 | Q9UBM7 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18644374 | 0.94 | NOTUM (0.41) | NOTUMGPR183SMN1; SMN2MEN1LMNA | |
| SCHEMBL13968936 | 0.93 | NOTUM (0.42) | NOTUMSMN1; SMN2MEN1LMNAKMT2A | |
| SCHEMBL12459703 | 0.93 | NOTUM (0.38) | NOTUMGPR183SMN1; SMN2MEN1LMNA | |
| SCHEMBL12459606 | 0.92 | SMN1; SMN2 (0.35) | NOTUMGPR183SMN1; SMN2HDAC1HDAC6 | |
| SCHEMBL13968991 | 0.92 | NOTUM (0.39) | NOTUMGPR183SMN1; SMN2MEN1LMNA | |
| SCHEMBL12459700 | 0.92 | NOTUM (0.40) | NOTUMSMN1; SMN2MEN1LMNAKMT2A | |
| SCHEMBL12459707 | 0.91 | NOTUM (0.40) | NOTUMSMN1; SMN2MEN1LMNAKMT2A | |
| SCHEMBL12459563 | 0.91 | L3MBTL1 (0.39) | GPR183SMN1; SMN2MEN1KMT2A | |
| SCHEMBL12459579 | 0.90 | NOTUM (0.40) | NOTUMSMN1; SMN2MEN1LMNAKMT2A | |
| SCHEMBL13968931 | 0.90 | NOTUM (0.42) | NOTUMSMN1; SMN2MEN1LMNAKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9598412-B2 | Spiroindoline compounds for use as anthelminthics | INTERVET INC. (US) | 2017-03-21 | — | — | US | disclosed |
| US-9598412-B2 | Spiroindoline compounds for use as anthelminthics | INTERVET INC. (US) | 2017-03-21 | — | — | US | disclosed |
| US-20150057302-A1 | SPIROINDOLINE COMPOUNDS FOR USE AS ANTHELMINTHICS | INTERVET INC. | 2015-02-26 | — | — | US | disclosed |
| US-20150057302-A1 | SPIROINDOLINE COMPOUNDS FOR USE AS ANTHELMINTHICS | INTERVET INC. | 2015-02-26 | — | — | US | disclosed |
| US-20120295931-A1 | SPIROINDOLINE COMPOUNDS FOR USE AS ANTHELMINTHICS | INTERVET INC. | 2012-11-22 | — | — | US | disclosed |
| US-20120295931-A1 | SPIROINDOLINE COMPOUNDS FOR USE AS ANTHELMINTHICS | INTERVET INC. | 2012-11-22 | — | — | US | disclosed |
| WO-2011095581-A1 | S PIROINDOLINE COMPOUNDS FOR USE AS ANTHELMINTHI CS | INTERVET INTERNATIONAL B.V. (NL) | 2011-08-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150057302-A1 | SPIROINDOLINE COMPOUNDS FOR USE AS ANTHELMINTHICS | PKD2, PKD1, PIR | NOTUM 1354/4885GPR183 518/4885SMN1; SMN2 3833/4885 |
| US-20120295931-A1 | SPIROINDOLINE COMPOUNDS FOR USE AS ANTHELMINTHICS | PKD2, PKD1, PIR | NOTUM 1354/4885GPR183 518/4885SMN1; SMN2 3833/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.